

SOURCE: Neptune Technologies & Bioresources Inc.

Neptune Provides Update on Sherbrooke Plant

Laval, Québec, CANADA – March 27, 2014 – Neptune Technologies & Bioresources Inc. (“Neptune” or the “Corporation”) (NASDAQ.NEPT - TSX.NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.

The Corporation continues to work with various government authorities, including those related to workers health & safety and the environment, to obtain all remaining permits to begin operations. Neptune has been actively working with these agencies during the construction process and has cooperated with them to implement their recommendations.

The new facility will have the capacity to produce more than 150 metric tons of krill oil annually. In addition, the plant has the required space to allow for a doubling of production capacity in the future, depending on demand.

About Neptune Technologies & Bioresources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (“PUFAs”). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune respectively holds approximately 49% of the participating and voting rights of Acasti and 96% of the voting rights of NeuroBioPharm. Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre[®], a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune and NeuroBio’s public securities

filings with the Securities and Exchange Commission and the Canadian securities commissions. Except as required by law, Neptune and NeuroBio disclaim any intention or obligation to update or revise any forward-looking statements.

"Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release."

Neptune Contacts:

André Godin

Chief Financial Officer

+1.450.687.2262

a.godin@neptunebiotech.com

neptunebiotech.com

John Ripplinger

Investor Relations

+1.450.687.2262

j.riplinger@neptunebiotech.com

neptunebiotech.com